CVS Caremark Settles FTC Insulin Lawsuit, CVS Got Paid More When Insulin Cost More. The FTC Is Forcing That to Stop.

CVS Health’s pharmacy benefit manager, Caremark, reached a proposed settlement with the Federal Trade Commission on March 24, 2026, becoming the second of the three largest drug middlemen in the U.S. to resolve federal allegations that their business practices drove insulin prices higher — and then profited from the result. 

The proposed consent agreement was disclosed in a joint motion from the FTC and CVS for Caremark and its group purchasing organization Zinc to withdraw from the case while regulators consider the deal. There is no cash payout for patients — but the settlement, if finalized, would require CVS to fundamentally change how it prices and covers drugs.

Field	Detail
Defendant	CVS Health / Caremark Rx / Zinc Health Services
Regulator	Federal Trade Commission (FTC)
Original Lawsuit Filed	September 2024
Proposed Settlement Date	March 24, 2026
Settlement Terms	Structural business reforms — no cash fine
Projected Patient Savings	Up to $7 billion over 10 years (based on Express Scripts model)
Settlement Status	Proposed — pending FTC chair review and final approval
Finalization Timeline	Expected within weeks
Who Else Settled	Express Scripts (Cigna) — February 4, 2026
Still Fighting	OptumRx (UnitedHealth Group)

Where Things Stand Right Now

• CVS’s proposed settlement is pending review and approval by the FTC chair — final terms are not yet public.
• A source familiar with the terms told Reuters the CVS settlement is in line with the agreement the FTC reached with Express Scripts last month.
• If CVS reaches a final settlement, UnitedHealth’s OptumRx would be the lone holdout in the high-profile suit.

You Paid Full Price. CVS Pocketed the Discount. Here Is How That Actually Worked.

Most people know their insulin is expensive. Far fewer know why — and the answer involves a system that runs entirely in the background of every prescription you fill.

A pharmacy benefit manager, or PBM, is the company your health insurer hires to manage your drug coverage. PBMs decide which drugs appear on your plan’s formulary — the approved list — and they negotiate with drug manufacturers for rebates, which are essentially bulk discounts paid after a drug is dispensed. In theory, those savings flow to you. In practice, the FTC says they didn’t.

The FTC alleged that the PBMs’ practices “artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable patients.” According to the complaint, the PBMs leveraged their ability to exclude certain products from restrictive formularies, demanding higher rebates from pharmaceutical manufacturers in exchange for placing products on their formularies.

Here is the perverse result: insulin makers responded by raising list prices so they could offer bigger rebates and stay on the formulary. The PBM collected more in rebate dollars. And you — the patient — paid your copay or coinsurance as a percentage of that inflated list price, not the net price after the rebate. The average list price for Humalog increased more than 1,200% from 1999 to 2017. The rebate system, designed to create competition, did the opposite. It created a race to the top on list prices.

The FTC’s complaint alleges that this system pushed insulin manufacturers to compete for preferred formulary coverage based on the size of rebates off the list price rather than net price, which ultimately benefited the PBMs — which kept a portion of the inflated rebates — while harming patients whose out-of-pocket payments like copays and coinsurance are tied to the list price of the drug.

Related article: Kim Kardashian and Kris Jenner Went to Court to Hide a $6M Settlement. The Judge Said No

No Cash Payout — But CVS Has to Change How It Does Business

This settlement does not put money directly in patients’ pockets. There is no claim form, no deadline, and no check coming in the mail. What it does — modeled on the terms already agreed to by Express Scripts — is restructure the financial incentives that drove prices up in the first place.

The Express Scripts settlement requires the company to delink drug manufacturers’ compensation from list prices as part of its standard offering, stop preferring drugs with the highest list prices, and take other steps the FTC says should save patients taking insulin up to $7 billion in out-of-pocket costs over a decade.

The Cigna settlement also required the company to adopt more transparency and shift to a fee-based compensation structure. Regulators say the previous model incentivized higher list prices and steering — driving larger discounts for the PBM while raising costs for patients.

CVS’s deal is expected to carry the same core requirements. J.P. Morgan analyst Lisa Gill wrote that she does not anticipate any financial penalty, and that with CVS already moving to a transparent cost-plus model over the next few years, nothing agreed to with the FTC would be materially different from what CVS had already proposed. For patients, that is both reassuring and frustrating — reassuring because the transition is already underway, frustrating because it confirms the old model ran for decades before regulators moved to stop it.

Two of Three Have Settled. UnitedHealth Is the Last One Still Fighting.

The FTC filed its lawsuit against the three largest PBMs — Caremark Rx, Express Scripts, and OptumRx — and their affiliated group purchasing organizations in September 2024, alleging they engaged in anticompetitive and unfair rebating practices that artificially inflated the list price of insulin drugs.

Together, these three PBMs administer approximately 80% of all prescriptions in the United States. That concentration is precisely why the FTC targeted them — a change to their standard practices reaches virtually the entire insured population.

Express Scripts settled in February. CVS reached its proposed deal in March. That leaves UnitedHealth’s OptumRx as the sole holdout in the high-profile suit. OptumRx has not announced settlement discussions. Its parent company, UnitedHealth Group, is also currently under scrutiny on separate fronts following the aftermath of the Change Healthcare cyberattack and ongoing Medicare Advantage billing investigations — meaning the pressure on UnitedHealth from all directions is significant heading into any continued FTC litigation.

What Diabetics and Plan Members Should Actually Expect

The honest answer is: meaningful change, on a slow timeline.

CVS Caremark covers tens of millions of Americans through employer health plans, Medicare Part D, and Medicaid managed care. The settlement’s reforms — if finalized and fully implemented — would recalculate patient cost-sharing based on net drug prices rather than inflated list prices. That is a structural shift that, over time, could reduce what diabetics pay at the pharmacy counter.

Express Scripts has until 2027 to comply with most of the settlement’s provisions, until 2028 to comply with transparency requirements and the cost-plus model shift, and will be subject to monitoring for 10 years under the deal. CVS’s timeline will be confirmed once final terms are published. Patients should not expect overnight changes at the pharmacy counter — but the direction of the industry is now set by two consent decrees and a third company still in the FTC’s crosshairs.

FAQs: CVS, the FTC, and What This Means for Insulin Prices

Is there a claim form I can file to receive money from this settlement? 

No. This is a regulatory enforcement action that requires CVS to change its business practices — not a consumer class action with cash payouts. There is no claim deadline, no settlement administrator, and no check for patients. The benefit is structural: lower drug costs over time as the rebate model is unwound.

What is a PBM and why does it affect what I pay for insulin?

 A pharmacy benefit manager (PBM) is the company your health insurer hires to manage prescription drug coverage — deciding which drugs are covered and negotiating prices with manufacturers. The FTC’s case is built on the allegation that PBMs like Caremark had a financial incentive to favor expensive drugs over cheaper ones because bigger list prices generated bigger rebates for the PBM, while patients paid copays calculated on those inflated prices.

Will my insulin cost less after this settlement?

 Potentially, yes — but gradually. The settlement requires CVS to shift patient cost-sharing to net drug prices (after rebates), stop favoring high-list-price drugs, and increase pricing transparency. Those changes take effect over a multi-year implementation period. The FTC projects the reforms could reduce insulin patients’ out-of-pocket costs by up to $7 billion nationally over a decade.

Is this settlement final?

 Not yet. A CVS spokesperson confirmed the proposed agreement is subject to review and approval by the FTC chair, and that final terms are still pending. CVS expects the process to wrap up within weeks.

What about OptumRx — does the CVS settlement affect UnitedHealth customers?

 No. OptumRx, which covers UnitedHealth Group’s members, has not settled and remains a defendant in the FTC’s ongoing case. Patients covered by UnitedHealth plans through OptumRx are not covered by the CVS or Express Scripts settlements.

Is this settlement legitimate? 

Yes. The FTC and CVS filed a joint motion in federal court disclosing the proposed consent agreement, and the case is part of a formally docketed FTC administrative action that began in September 2024. The Express Scripts settlement was published in full on the FTC’s official website at ftc.gov.

Do I need a lawyer to benefit from this?

 No. If CVS’s reforms lower your insulin’s net cost-sharing, that change will flow automatically through your health plan without any action on your part. If you believe your insurer or PBM has separately wronged you — for example, by denying coverage for a lower-cost insulin — you may want to consult a patient advocate or attorney, but this settlement does not require individual legal action.

Will a settlement payment affect my taxes? 

There is no cash settlement payment to patients from this case, so there is no tax impact. If future regulatory changes or plan adjustments reduce your drug costs, lower copays are not taxable income.

Sources

• FTC Official Press Release: FTC Secures Landmark Settlement with Express Scripts (February 4, 2026)
• FTC PBM Case Page: https://www.ftc.gov/terms/pharmacy-benefits-managers-pbm

Last Updated: April 2, 2026

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Legal claims and outcomes depend on specific facts and applicable law. For advice about a particular situation, consult a qualified attorney.